Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine versus oral cyclophosphamide + capecitabine in advanced breast cancer
ISRCTN68662102Phase 2Completed
- Sponsor
- Cancer Trials New Zealand
- Start
- Jan 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Oral cyclophosphamide + capecitabine with Capecitabine alone (2 arms). Primary endpoints: Toxicity and Best tumour response. Started Jan 2004; status: completed.
02
Drugs
capecitabinecyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN68662102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68662102.